Description: This webcast will provide an overview of the types of ethical issues that pension actuaries may face throughout their careers and dive into specific examples of how to navigate and potential responses to such issues.

Description: Short Form Professional Development Videos - PD Edge Pod IFRS 17 Building Blocks Recording

Description: Recording for Life Insurance Riders

Description: General Session – Challenges of Asset Intensive Reinsurance

Description: The actuarial profession is changing rapidly and the skills needed to be successful are also changing. In this session, we will debate key topics and questions, such as: What is the predominant future career path for actuaries? Specialists or generalists? Does the actuarial profession have a meaningful value prop outside our core domains e.g. insurance? What skills are needed for the actuary of the future? What’s the best approach to improve actuarial storytelling to non-actuarial audiences? What’s the role of actuaries to managing and predicting emerging trends and assumptions? What is the role of actuaries in relation to development and ownership of advanced modeling? Is the future actuarial profession smaller/larger than it is today? In either case, how does it differ from today in terms of make-up, deployment, function, purpose, value add, etc.?

Description: In this video Mitchell Momanyi, FSA MAAA presents an informative breakdown of Medicare Advantage plans, delving into the intricacies of this alternative to traditional Medicare. Covering the inception of Medicare Advantage and its evolution, Momanyi explores the managed care companies offering Part C coverage, emphasizing the role of provider networks coordinated care. Concluding with key considerations for beneficiaries, Momanyi stresses the importance of weighing the pros and cons between Traditional Medicare and Medicare Advantage, while also emphasizing the evolving nature of the Medicare landscape and the regulatory nuances influencing enrollment decisions. Conributors: Mitchell Momanyi, FSA, MAAA, Deana Bell FSA, MAAA, Matt Emery, FSA, CERA, MAAA, Jon Forster, ASA, MAAA

Description: In this video Dale Hall, Managing Director of Research at the Society of Actuaries Research Institute, introduces a report titled “Guide to Domestic & International Paid Family and Medical Leave Programs.” Motivated by the increasing interest in these programs, especially post-COVID 19, the report compares U.S. and international paid family and medical leave initiatives. Key findings include differences in benefit generosity and periods for maternity and paternity leave, as well as domestic violence leave. Contributors: Dale Hall FSA, MAAA, CFA, CERA , Rose Northon, STeven Siegel ASA MAAA, Jon Forster ASA MAAA

Description: Creating a predictive model is one thing, but then taking that model and getting full stakeholder buy-in is another. Learn from presenters' experiences and insights on proving model effectiveness in the long-term care (LTC), life and annuity spaces. Explore various topics such as feasibility, model transparency, fairness and equity, ROI measurement, data assets and compliance, infrastructure and more. By the end of the session, you will gain an understanding of how to navigate the challenges of proving the effectiveness of predictive modeling and obtaining management buy-in.

Description: Cover a variety of topics centered around the unsupervised learning technique called 'clustering'. The presenters will take you through a wide array of topics that range from 'What is Clustering?' to 'How can I use this technique to solve problems I didn't even know existed?' In the health care industry, everyone is looking for an edge in reducing total spend-cluster analysis finds the unambiguous in an ambiguous framework of results.

Description: Hear about the new hope biosimilars bring in helping payers and patients manage the rapidly growing pharmacy spend. The Big Event, encompassing multiple Humira biosimilars, launches in 2023 and could set the tone for how much biosimilars can be expected to contribute to solving our pharmacy spend challenges. What will be the financial impact of the Big Event and this coming wave? What can be done to maximize adoption of biosimilars? What strategies are available to maximize savings for payers and patients?